2025 Exudative Retinal Disease Pharmaceuticals Market Report, October, 2025

The “2025 Exudative Retinal Disease Pharmaceuticals Market Report” delivers a comprehensive analysis of anti-VEGFs and other therapies for exudative retinal diseases. It highlights key market trends, growth drivers, and future opportunities, with five-year forecasts in units and dollars for branded ocular anti-VEGFs, cancer drugs used off-label, biosimilars, and sustained-drug-delivery devices. The report also breaks down market share by product category and profiles 29 leading competitors, detailing their products, strategies, and market positioning. 

The “2025 Exudative Retinal Disease Pharmaceuticals Market Report” provides a comprehensive view of the market for therapies targeting wet AMD and other exudative retinal diseases. Designed to give readers both depth and context, the report covers the full spectrum of disease understanding, treatment options, and market dynamics. 

Key areas of coverage include: 

• Disease landscape: Retinal diseases and their risk factors, plus diagnosis and treatment trends. 
• Global perspective: Retina specialists and patterns of care across major markets. 
• Current therapies: Pharmaceuticals and biologics already on the market for exudative retinal diseases. 
• Pipeline insights: Investigational agents under development, across multiple mechanisms of action. 
• Competitive landscape: Profiles of companies marketing therapies, plus additional firms with preclinical programs. 
• Detailed market forecasts for: Branded ocular anti-VEGFs, cancer drugs used off-label, biosimilars for exudative retinal diseases, and sustained-drug-delivery devices 

The report also analyzes the development pipelines across eight pharmaceutical categories: 

• VEGF inhibitors 
• Other vascular growth factor inhibitors 
• Plasma kallikrein inhibitors 
• Gene therapies 
• Cell therapies 
• Anti-inflammatories 
• Wnt signaling modulators 
• Other mechanisms of action 

This structured approach gives readers a clear understanding of current opportunities, emerging trends, and future growth potential in the exudative retinal disease segment. 

2 licensing types are available for this report:

• The price of the single-user license is $8,800.
• The price of the enterprise license is $13,200 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

• The Single User License allows for the use of a report by a single user within one corporate location.
• The report paper copy may not be reproduced (additional paper copies available for purchase).
• Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
• Only a single copy of the publication may be printed for internal use.
• Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

• The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
• Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
• Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
• Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.

Pay by credit card or by invoice.